Phase 2 Central Nervous System Clinical Trials
48 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 48 trials
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 1Phase 2
A Study of Mirdametinib in People With Central Nervous System Tumors
GliomaCentral Nervous System Tumors
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07539441
Recruiting
Phase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled3 locationsNCT07326566
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1Phase 2
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2
ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
Lymphoma Patients With High-risk of Central Nervous System Relapse
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07481669
Recruiting
Phase 2
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD133 enrolled1 locationNCT04276870
Recruiting
Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 2
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 2
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Central Nervous System NeoplasmMetastatic Malignant Neoplasm in the BrainCranial Nerve Disorder
OHSU Knight Cancer Institute150 enrolled1 locationNCT03270059
Recruiting
Phase 1Phase 2
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Lymphoma+7 more
Children's Oncology Group63 enrolled34 locationsNCT04870944
Recruiting
Phase 2
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Central Nervous System Nongerminomatous Germ Cell TumorChoriocarcinomaEmbryonal Carcinoma+7 more
Children's Oncology Group160 enrolled165 locationsNCT04684368
Recruiting
Phase 2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Phase 2
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 1Phase 2
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Central Nervous System Lymphoma
Tong Chen, MD30 enrolled5 locationsNCT05698147